Affordable Access

Publisher Website

Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function

Molecular and Cellular Endocrinology
Publication Date
DOI: 10.1016/j.mce.2006.04.012
  • Central Precocious Puberty
  • Depot Gnrh Agonist
  • Hyperandrogenism
  • Reproductive Function
  • Ecology
  • Medicine


Abstract Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with central precocious puberty (CPP). It is still unclear whether long-term exposure to GnRHa is associated with impaired reproductive function in adulthood. The present study was performed on 46 women, former CPP patients, 12.5 ± 3.7 years after the discontinuation of treatment with depot GnRHa. In a structured interview, we assessed general health status, clinical signs possibly associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function. It appears that long-term treatment with depot GnRHa is safe and does not impair reproductive function. The risk of former CPP patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal population but this issue needs to be addressed in further long-term follow-up studies.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Long-term GnRH agonist treatment for female centra...

on Molecular and Cellular Endocri... Jul 25, 2006

Long-term GnRH-agonist treatment does not postpone...

on The Journal of Clinical Endocr... May 1995

Final height in central precocious puberty after l...

on Archives of Disease in Childho... October 1996

Long-term results of GnRH analogue (Buserelin) tre...

on Acta paediatrica Scandinavica November 1985
More articles like this..